TG Therapeutics (TGTX)

The company’s key marketed product is BRIUMVI, the brand name for ublituximab-xiiy. BRIUMVI is an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The medicine has also received regulatory approvals in markets outside the United States. TG Therapeutics generates most of its revenue from U.S. sales of BRIUMVI, with additional contribution from international markets.

TG Therapeutics’ pipeline is built around expanding the potential of ublituximab and advancing additional immune-based therapies. Programs include ublituximab, a subcutaneous formulation of ublituximab intended to provide a different route of administration, and AZER-CEL, a cell therapy candidate. These assets reflect the company’s broader strategy of targeting diseases where B-cell depletion or immune modulation may offer clinical benefit.

The company operates in a highly regulated and competitive biotechnology market, where adoption depends on clinical data, physician confidence, reimbursement, safety profile, and differentiation from established multiple sclerosis therapies. TG Therapeutics is distinctive because it has moved beyond development-stage biotech status and now relies on the commercial performance of an approved neurology product while continuing to build a focused B-cell disease pipeline.